Brief: Cereno Scientific Receives Approval To Initiate FDA-Aligned Phase I Pharmacokinetic Study Of Cs014 Supporting Phase Ii Development In Ph-Ild
17/03/2026 11:44
March 17 (Reuters) - Cereno Scientific AB CRNOSb.ST: CERENO SCIENTIFIC RECEIVES APPROVAL TO INITIATE FDA-ALIGNED PHASE I PHARMACOKINETIC STUDY OF CS014 SUPPORTING PHASE II DEVELOPMENT IN PH-ILD Source text: ID:nPn5K6lw6a Further company coverage: [CRNOSb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Expects Up To 15 Activated Sites By 2026 In Epimode Trial
Brief: Cereno Scientific Reports Positive Results From Study
Brief: Cereno Scientific Q2 Net Sales Sek 0
Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 30.5 Mln